Clinical Trial Update: Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating PCSK9 inhibition on coronary perfusion in coronary artery disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: ECRI bv | Conditions: Coronary Artery Disease | Phase 4 | Status: WITHDRAWN